CNS Therapy Development for Lysosomal Storage Disorders (R01)

The summary for the CNS Therapy Development for Lysosomal Storage Disorders (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
CNS Therapy Development for Lysosomal Storage Disorders (R01): Purpose. The goal of this Funding Opportunity Announcement (FOA) is to solicit applications on lysosomal storage disorders (LSDs) focused on improving CNS treatment outcomes, enhancing the effectiveness of delivery and targeting of cells, enzymes, drugs and genes into the brain, and developing novel therapeutic modalities, such as implantable biocapsules and micro-electro-mechanical systems (MEMS)-based devices. Lysosomal storage disorders constitute a group of recessive genetic diseases resulting from cellular enzymatic deficiencies of acid hydrolases that normally catalyze the metabolism of glycoproteins, glycolipids and other macromolecules, or from defects in transporter proteins leading to pathogenic accumulation of these substances in lysosomes. Treatment modalities for LSDs are currently limited to bone marrow transplantation (BMT) and enzyme replacement therapy (ERT). These approaches while providing significant promise for treatment of the visceral manifestations of LSDs, do little to address CNS pathologies for this group of disorders. Thus this announcement specifically encourages the transition from basic studies in LSDs to translational research for improved delivery of therapeutic cells, proteins, genes, and small molecules across the blood-brain barrier. Mechanism of Support. This FOA will utilize the Research Project Grant (R01) award mechanism, and runs in parallel with an FOA of identical scientific scope (PAS-06-202) that solicits applications under the exploratory/developmental grant award (R21) mechanism. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The NINDS and ORD intend to commit a total of approximately $1,050,000 (total costs), in addition to funds available for applications sent in response to this FOA and a parallel R21 FOA (see above) that score within the NINDS payline (see NINDS Funding Strategy http://www.ninds.nih.gov/funding/ninds_funding_strategy.htm), depending on the overall scientific merit of the applications and the availability of funds throughout the duration of this solicitation. Additional funds may also be available through the Lysosomal Storage Disease Research Consortium (http://www.LSDresearch.org) for applications received and reviewed under this FOA. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. Each R01 project is limited to a duration of five years. Eligible Institutions/Organizations. Public/State Controlled Institution of Higher Education; Private Institution of Higher Education; Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education); Nonprofit without 501(c)(3) IRS Status (Other than Institution of Higher Education); Small Business; For-Profit Organization (Other than Small Business); State Government; U.S. Territory or Possession; Indian/Native American Tribal Government (Federally Recognized); Indian/Native American Tribal Government (Other than Federally Recognized); Indian/Native American Tribally Designated Organization; Non-domestic (non-U.S.) Entity (Foreign Organization); Hispanic-serving Institution; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); Alaska Native and Native Hawaiian Serving Institutions; Regional Organization; Other(s): Eligible agencies of the Federal government; Faith-based or community based organizations.
Federal Grant Title: CNS Therapy Development for Lysosomal Storage Disorders (R01)
Federal Agency Name: National Institutes of Health
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: PAS-07-195
Type of Funding: Grant
CFDA Numbers: 93.853
CFDA Descriptions: Extramural Research Programs in the Neurosciences and Neurological Disorders
Current Application Deadline: No deadline provided
Original Application Deadline: Multiple Receipt Dates - See Link to Full Announce
Posted Date: Dec 18, 2006
Creation Date: Sep 18, 2007
Archive Date: Feb 07, 2008
Total Program Funding: $1,050,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
City or township governments State governments County governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Others (see text field entitled "Additional Information on Eligibility" for clarification) Public and State controlled institutions of higher education Small businesses Private institutions of higher education Special district governments Public housing authorities/Indian housing authorities Independent school districts Native American tribal organizations (other than Federally recognized tribal governments)
Additional Information on Eligibility
Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply.
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
NIH OER Webmaster
[email protected]
[email protected] If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants
Mechanisms of Cognitive Fluctuations in ADRD Populations (R01 - Clinical Trial Optional)
NINDS Advanced Institutional Research Training Program (T32 Clinical Trial Not Allowed)
Institutional Translational Research Training Program (T32 - Clinical Trial Not Allowed)
Translational Neural Devices (R61/R33 - Clinical Trial Optional)
Development and Validation of Human Cellular Models for Alzheimer's Disease-Related Dement...
NINDS Cooperative Small Business Awards In Translational Research (SBIR/U44)
NINDS Institutional Center Core Grants to Support Neuroscience Research
Career Development Award to Promote Diversity in Neuroscience Research
More Grants from the National Institutes of Health
HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...
Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...
Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...
AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com